TABLE.

Plasma AVP, Copeptin, and Sodium Concentrations in Hyponatremic and Normonatremic Ultradistance Runners Participating in 3 Separate Trials

Trial Measurement (N)	[AVP]p, Mean ± SD (Minimum-Maximum), pg/mL	[Copeptin]p, Mean ± SD (Minimum-Maximum), pmol/L	[Na+]p, Mean ± SD (Minimum-Maximum), mEq/L
WSER Sodium Balance Trial, prerace (6 normonatremic)	0.7 ± 0.4 (0.2–1.1)	10.3 ± 12.5 (2.1–34.9)	138.7 ± 2.3 (136–142)
WSER Sodium Balance Trial, postrace (6 normonatremic)	2.7 ± 1.9 (1.4–6.4)	28.2 ± 16.2 (3.6–52.1)	136.7 ± 1.6 (135–139)
WSER Hyponatremia Trial, pretreatment (6 hyponatremic)	3.2 ± 2.9 (0.3–6.9)	22.5 ± 27.5 (2.9–73.0)	130.3 ± 2.6 (126–133)
WSER Hyponatremia Trial, posttreatment (6 hyponatremic)	2.1 ± 2.5 (0.5–7.1)	24.9 ± 39.7 (2.8–105.0)	133.5 ± 3.4 (127–136)
JJ100 Sodium Balance Trial, prerace14	0.8 ± 0.5 (0.5–2.4)	5.0 ± 2.9 (1.4–10.4)	141.4 ± 2.2 (137–145)
JJ100 Sodium Balance Trial, 50 km14	2.7 ± 2.0 (0.8–7.1)	17.8 ± 13.3 (1.2–47.5)	143.4 ± 3.5 (137–149)
JJ100 Sodium Balance Trial, 100 km14	1.2 ± 0.6 (0.3–2.1)	16.5 ± 13.8 (2.2–35.8)	139.6 ± 3.2 (132–144)
JJ100 Sodium Balance Trial, 162 km7	1.8 ± 1.1 (0.4–4.0)	19.4 ± 17.3 (3.1–51.8)	138.9 ± 2.0 (137–143)